...Functional biology company Tranzyme and medicinal chemistry play Neokimia will merge in a 50-50 share deal...
...axis." Tranzyme has one preclinical compound and another in lead optimization in undisclosed neurology indications. Neokimia...
...will remain Tranzyme president and CEO. Caroline Fortier, president and CEO of Neokimia, will depart. Neokimia Inc....

...Functional biology company Tranzyme ( Research Triangle Park, N.C.) and medicinal chemistry play Neokimia (Sherbrooke, Quebec...
...axis." Tranzyme has one preclinical compound and another in lead optimization in undisclosed neurology indications. Neokimia...
...programs. Vipin Garg will remain Tranzyme president and CEO. Caroline Fortier, president and CEO of Neokimia...

...Infectious Hired: Robert Deziel as VP of discovery chemistry, formerly senior director of research at Neokimia Inc. WIR...

...develop small molecule HIV fusion inhibitors. TRMS will screen a library of small molecules from NeoKimia...
...research costs, and TRMS will be responsible for clinical development and regulatory and commercial activities. NeoKimia...
...co-fund clinical development of resulting compounds through Phase I trials, in exchange for increased royalties. NeoKimia Inc....

...TRMS and Neokimia (Sherbrooke, Quebec) partnered to research and develop small molecule HIV fusion inhibitors. TRMS...
...develop small molecule HIV fusion inhibitors. TRMS will screen a library of small molecules from Neokimia...
...research costs, and TRMS will be responsible for clinical development and regulatory and commercial activities. Neokimia...

...will use its Bacto III purified DNA polymerase screens and Replix cell-based screen to evaluate NeoKimia’s...
...The companies will jointly optimize the structures of active compounds. Microbiotix Inc. , Worcester, Mass. NeoKimia Inc....

...and Replix cell-based screen to evaluate a library of macrocyclic bacterial DNA synthesis inhibitors from NeoKimia...